Objective We assessed the impact of direct-acting antiviral (DAA) therapy on liver fibrosis
regression measured by transient elastography (TE) in patients with chronic hepatitis C virus (…

Background In April 2015, in collaboration with the US Centers for Disease Control and
Prevention and Gilead Sciences, the country of Georgia embarked on the world’s first hepatitis C …

Objectives Georgia introduced remdesivir for the treatment of COVID-19 in December 2020.
We evaluated the real-world effect of remdesivir on mortality and the need for mechanical …

Late presentation for HIV care has important individual and population implications. The
objective of this study was to explore the problem of late presentation in the country of Georgia. …

Introduction Hepatitis C virus (HCV) infection is a serious health problem in Georgia. Methods
We conducted a prospective study to identify and characterize the natural history of recent …

METHODS From May 2018 through July 2021, a total of 10 PHCs provided HCV care services
throughout the country. The integrated model was based on a “one‐stop‐shop” approach, …

In order to describe HIV‐1 subtypes and drug resistance mutations in Georgia, blood samples
from 153 patients infected with HIV‐1 collected from 2006 to 2008 were genotyped. Of …

Background Georgia has one of the highest HCV prevalence in the world and launched the
world’s first national HCV elimination programs in 2015. Georgia set the ambitious target of …

Objective Describe presenting characteristics of hospitalized patients and explore factors
associated with in-hospital mortality during the first wave of pandemic in Georgia. Methods This …

Since 2004, Georgia achieved universal access to free antiretroviral therapy (ART). A retrospective
cohort study was conducted to evaluate the outcomes of Georgia's ART program. The …